Google NewsSyntara (ASX:SNT): Myelofibrosis Trial Plans Put Clinical Pipeline in Focus - Kalkine
Syntara (ASX:SNT): Myelofibrosis Trial Plans Put Clinical Pipeline in Focus Kalkine
SNT
Syntara
Pharmaceuticals, Biotechnology & Life Sciences
Syntara Limited is a clinical-stage drug development company focused on creating novel treatments for blood-related cancers and conditions linked to inflammation and fibrosis. Their expertise lies in amine oxidase inhibitors, targeting extracellular matrix dysfunction to develop medicines for diseases with high unmet needs. The company's lead candidate, amsulostat, is currently in Phase 2 trials for myelofibrosis.
Short position
short percentage0.24%
reported shorts4.8M
shares on issue1.963B
Syntara (ASX:SNT) has 0.24% of its shares on issue reported as short positions as of 7 July 2026, or about 4,806,305 shares. Over the past 30 days that figure has risen 0.24 percentage points, and over 90 days it has risen 0.11 percentage points. SNT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Syntara (SNT) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXFurther significant results from SNT-4728 iRBD Phase 2 trial
other announcement
KalkineSyntara Limited Grants 1,581,746 Performance Rights to Employees, Including Key Executive Wolfgang Jarolimek
On 5 October 2026, Syntara Limited (ASX:SNT) announced the issuance of 1,581,746 unquoted performance rights under its employee incentive scheme, with 867,972 rights allocated to key management personnel Wolfgang Jarolimek. Key Highlights 1,581,746 performance rights (ASX code: SNTAAS) issued on 5 October 2026 as part of Syntara's employee incentive plan 867,972 performance rights granted to key management personnel Wolfgang Jarolimek as registered holder Rights issued with zero grant and exe...
Syntara Limited Grants 34.9 Million Performance Rights to Senior Executives and Key Employees
On 5 October 2026, Syntara Limited (ASX:SNT) issued 34,940,128 unquoted performance rights to senior managers and key staff as part of its employee incentive program. These securities remain unlisted on the ASX due to ongoing transfer restrictions. Key Highlights 34,940,128 performance rights (ASX code: SNTAAS) granted on 5 October 2026 under the Syntara Performance Rights Plan Three key management personnel received a total of 13,168,219 performance rights: Jana Baskar (4,346,312), Kristen M...
Notification regarding unquoted securities - SNT
other announcement
We Think Syntara (ASX:SNT) Needs To Drive Business Growth Carefully - Simply Wall Street
We Think Syntara (ASX:SNT) Needs To Drive Business Growth Carefully Simply Wall Street
Small CapsSyntara Expands Safety and Tolerability Study of SNT-9465 Topical Scar Treatment
Syntara expands Phase 1b trial for SNT-9465, adding 10 participants, new blinded design and Sydney site; top-line data due Q1 2027 to back an IND.
Syntara expands SNT-9465 skin scarring study
other announcement
Syntara receives A$4.7m R&D Tax Incentive
other announcement
Application for quotation of securities - SNT
other announcement
Syntara (ASX:SNT): Is the Market Missing Something? - Kalkine
Syntara (ASX:SNT): Is the Market Missing Something? Kalkine
Syntara Therapeutics Gains FDA Support and Raises $8M in Institutional Placement, Boosting Growth Outlook
Syntara Therapeutics has disclosed key advancements in its drug development pipeline, including favorable feedback from the US FDA on its amsulostat therapy for myelofibrosis. The company also completed an $8.0 million institutional placement, strengthening its financial foundation and extending its cash runway through FY28. These developments are vital for investors as they underscore Syntara's strategic progress and growth potential. Key Points Syntara Therapeutics Ltd (SNT) Received positi...
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Syntara (ASX:SNT) Shares Gain Attention After Neuroinflammation Study Update - Kalkine
Syntara (ASX:SNT) Shares Gain Attention After Neuroinflammation Study Update Kalkine
Syntara (ASX:SNT): Why Is the Biotech Company Expanding Its Listed Shares?
Highlights Syntara has applied for the quotation of newly issued ordinary shares on the Australian Securities Exchange. The additional listed securities are expected to expand the company's quoted share base. The move reflects an important capital market development as the biotechnology company continues advancing its corporate strategy. Syntara has applied to quote additional ordinary shares on the ASX, supporting its capital management strategy while continu...